On July 10, Twist Bioscience declined 5.18% in regular trading, trading at approximately $88.82/share, with turnover of $18.57 million.

On the news front, the company recently filed a proposed securities sale report indicating insider intent to reduce holdings. Simultaneously, the broader biotechnology sector came under significant selling pressure, with Moderna falling 8.2%, Ionis Pharmaceuticals declining 7.37%, and Argenx SE dropping 3.55%, creating a drag on individual stocks across the sector.

The decline was further amplified by short-term profit-taking, as the stock had risen 5.5% in the prior trading session to $94.83. Additionally, the company previously filed a shelf registration statement for the potential sale of up to $200 million of common stock under an at-the-market program, with ongoing dilution concerns continuing to weigh on market sentiment. Evercore ISI had also recently downgraded the stock from Outperform to In Line, despite raising its price target to $102, signaling limited near-term upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)